Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Next Previous
X
Search
Trial Profile

Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human dermal fibroblasts-SpinalCyte (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Therapeutic Use
  • Acronyms Landmark
  • Sponsors FibroGenesis

    • Most Recent Events

    • 28 Jan 2020 According to a SpinalCyte media release, the company has changed its name to FibroGenesis.
    • 28 Mar 2019 According to a SpinalCyte media release, the company announced that the data from this trial will be presented at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting (ISASS19) on Thursday, April 4, 2019 in Anaheim, CA. This will include the new 16th month data.
    • 25 Oct 2018 Results of a positive 12 month pain data published in the SpinalCyte Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top